CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

K. Beelen; M. Opdam; T.M. Severson; R.H.T. Koornstra; A.D. Vincent; M. Hauptmann; R.H.N. van Schaik; E.M.J.J. Berns; J.B. Vermorken; P.J. van Diest; S.C. Linn

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Translated title of the contribution: CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

K. Beelen, M. Opdam, T.M. Severson, R.H.T. Koornstra, A.D. Vincent, M. Hauptmann, R.H.N. van Schaik, E.M.J.J. Berns, J.B. Vermorken, P.J. van Diest, S.C. Linn

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
Original language	Undefined/Unknown
Pages (from-to)	649-655
Number of pages	7
Journal	Breast Cancer Research and Treatment
Volume	139
Issue number	3
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23736997

Cite this

Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Hauptmann, M., van Schaik, R. H. N., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., & Linn, S. C. (2013). CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 139(3), 649-655. http://www.ncbi.nlm.nih.gov/pubmed/23736997

@article{24b06c72e74f48d3ad72e4edefcca3f3,

title = "CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.",

author = "K. Beelen and M. Opdam and T.M. Severson and R.H.T. Koornstra and A.D. Vincent and M. Hauptmann and {van Schaik}, R.H.N. and E.M.J.J. Berns and J.B. Vermorken and {van Diest}, P.J. and S.C. Linn",

year = "2013",

language = "Undefined/Unknown",

volume = "139",

pages = "649--655",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "3",

}

Beelen, K, Opdam, M, Severson, TM, Koornstra, RHT, Vincent, AD, Hauptmann, M, van Schaik, RHN, Berns, EMJJ, Vermorken, JB, van Diest, PJ & Linn, SC 2013, 'CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.', Breast Cancer Research and Treatment, vol. 139, no. 3, pp. 649-655. <http://www.ncbi.nlm.nih.gov/pubmed/23736997>

TY - JOUR

T1 - CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

AU - Beelen, K.

AU - Opdam, M.

AU - Severson, T.M.

AU - Koornstra, R.H.T.

AU - Vincent, A.D.

AU - Hauptmann, M.

AU - van Schaik, R.H.N.

AU - Berns, E.M.J.J.

AU - Vermorken, J.B.

AU - van Diest, P.J.

AU - Linn, S.C.

PY - 2013

Y1 - 2013

M3 - Article

SN - 0167-6806

VL - 139

SP - 649

EP - 655

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -